Relationship between HuR and tumor drug resistance

Ma, Qiancheng; Lu, Qiliang; Lei, Xiangxiang; Zhao, Jie; Sun, Wen; Huang, Dongsheng; Zhu, Qing; Xu, Qiuran

doi:10.1007/s12094-023-03109-5

Cited by 4 publications

(2 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Widely expressed in vivo, ELAVL1 might stabilize target diverse oncogenic mRNAs or promote their translation and nucleocytoplasmic translocation, further partaking in cell growth, metastasis, and differentiation (Grammatikakis et al., 2017; Palomo‐Irigoyen et al., 2020). Lately, it has become evident that ELAVL1 is aberrantly expressed in different human cancers and acts as an essential factor in poor clinical prognosis (Ma et al., 2023; Wu & Xu, 2022). In terms of HCC, ELAVL1 might function as an RNA stabilizer to regulate the oncogene ETS1, thereby facilitating the proliferation and growth of tumor cells (Chen, Peng, et al., 2019).…”

Section: Introductionmentioning

confidence: 99%

Matrine inhibits cell proliferation, invasion, and stem cell formation in hepatocellular carcinoma by regulating the ELAVL1/RBM3‐mediated Wnt/β‐catenin signaling pathway

Song,

Li,

Huang

et al. 2024

Chem Biol Drug Des

View full text Add to dashboard Cite

Matrine has been reported to exert anti‐tumor effects in various cancers, including hepatocellular carcinoma (HCC). Nevertheless, the anti‐tumor molecular mechanism of Martine in HCC is still not fully revealed. Cell proliferative ability, apoptosis, invasion, and sphere formation ability were detected using 3‐(4, 5‐dimethyl‐2‐thiazolyl)‐2, 5‐diphenyl‐2‐H‐tetrazolium bromide (MTT), 5‐ethynyl‐2′‐deoxyuridine (EdU), flow cytometry, transwell, and sphere formation assays. CyclinD1, MMP2, RNA‐binding motif protein 3 (RBM3), embryonic lethal abnormal visual‐like protein 1 (ELAVL1), Wnt3A, and β‐catenin protein levels were assessed using western blot. RBM3 and ELAVL1 expression was measured using real‐time quantitative polymerase chain reaction (RT‐qPCR). After being predicted using Starbase, the possible interaction between ELAVL1 and RBM3 was identified using Co‐Immunoprecipitation (IP) assays. A xenograft model was used to examine how Matrine affects HCC cell growth in vivo. Matrine hindered HCC cell proliferation, invasion, and sphere formation ability, and boosted apoptosis in vitro. ELAVL1 and RBM3 content was decreased in Matrine‐treated HCC cells in a concentration‐dependent manner and was increased in HCC tissues and cell lines. Moreover, ELAVL1 might bind with RBM3 to positively regulate the stability of RBM3 mRNA. Matrine modulated the Wnt/β‐catenin signaling pathway by ELAVL1/RBM3 axis. Matrine blocked tumor growth in xenograft modes in vivo. Matrine suppressed HCC cell progression partly by regulating the ELAVL1/RBM3, providing the possible therapeutic strategy for HCC treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Matrine inhibits cell proliferation, invasion, and stem cell formation in hepatocellular carcinoma by regulating the ELAVL1/RBM3‐mediated Wnt/β‐catenin signaling pathway

Song,

Li,

Huang

et al. 2024

Chem Biol Drug Des

View full text Add to dashboard Cite

show abstract

“…Multiple other recent reviews have similarly discussed targeting HuR protein expression or function ( 6 - 8 ). Many studies show a synergistic effect between HuR targeting and chemotherapy in multiple different settings, including in breast, lung, colorectal, prostate, liver, pancreatic cancer and others ( 9 ).…”

mentioning

confidence: 99%